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Purpose/objective(s). Stereotactic body radiotherapy (SBRT), also known as stereotactic ablative radiotherapy (SABR), is now a
standard treatment option for patients with stage I non-small cell lung cancer (NSCLC) or oligometastatic lung tumors that are
medically inoperable, old or who refuse surgery. The aim of this study is to present our initial experience with SBRT for NSCLC
patients treated with volumetric modulated arc therapy (RapidArc).
Materials/methods. From August to December 2012, three-male patients with early-stage NSCLC were treated with SBRT. The
mean age was 80.3 years old. All of them had histological conﬁrmation: squamous cell carcinoma in two cases and NSCLC not
otherwise speciﬁed in the other one. A slow CT scan of 2mm thickness was performed to consider the tumor motion and deﬁne
the PTV. Patients lie in a stable and comfortable position (arms above their head and below-knee support), allowing accuracy
reproducibility between fractions. The SBRT schedule was 60Gy in 8 fractions using 2-arc RapidArc plan. A CBCT was acquired
daily before each treatment.
Results. Mean tumor diameter was 2.76 cm (range, 1.5–3.7 cm) and mean PTV volume was 99.05 cm3 (range, 30.56–171.8 cm3).
For the PTV, mean D50%, D2% and D98% were 60.9Gy (range, 60.9–61.2Gy), 62.51Gy (range, 62–63.2Gy) and 57.43Gy (range,
56.4–58.1Gy) respectively. Mean lung dose (MLD) and mean V13 and V20 of both lungs excluding the PTV was 5.84Gy, 14.16% and
9.05% respectively. No acute toxicity was observed according to the Common Terminology Criteria for Adverse Events (CTCAE
V.4.0).
Conclusions. RapidArc for SBRT achieved a good conformity to target and a sharp dose fall-off in normal tissues in a short delivery
time. After this initial evaluation, acute toxicity is comparable to other series, but we need to recruit a greater number of patients
with a longer follow-up to establish long-term results.
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